# US 2024/0199624 A1 · Compounds, compositions, and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199624 A1
- Document ID: US20240199624A1
- Status: Published application
- Kind: A1
- Application number: 18/521,696
- Filed: 2023-11-28
- Published: 2024-06-20
- Earliest claimed: 2022-11-29
- Assignees: CHDI Foundation, Inc.
- Applicants: CHDI Foundation, Inc.
- Inventors: Tasir Haque; Michel Maillard; Gareth Brace; George Ballantyne; Elizabeth Frush; Kim Hirst; Katherine Jones; Emanuela Gancia; Chris Lock; Cole Clissold
- Web page: https://patentgrep.com/patent/US20240199624A1

## CPC

- C07D 475/08: with a nitrogen atom directly attached in position 2
- C07D 487/04: Ortho-condensed systems
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to small molecule inhibitors of MutSβ protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, or 5;
p is 0, 1, 2, 3, 4, or 5;
q is 0, 1, 2, 3, or 4; provided that p+q is 2, 3, 4, or 5;
L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
X1 is CR5 or N;
R1 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R2 is halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R5 is hydrogen, C1-6 alkyl, or —N(R11)2;
each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; and
each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl;
provided that:
when L is —NH—, R3 and R4 are both hydrogen, and the moiety
then the moiety

### Claim 2 (depends on 1)

The compound of claim 1, wherein p+q is 3 or 4.

### Claim 3 (depends on 1)

The compound of claim 1, wherein p is 2 and q is 2.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula IA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X1 is N.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is C1-6 alkyl optionally substituted with 1-5 R10.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula IB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L is —NH—.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula IC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 12 (depends on 1)

The compound of claim 1, wherein n is 0 or 1.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula ID:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula IE:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R2 and R2a are each independently halo or C1-6 alkyl.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The compound of claim 13, wherein the moiety
is:

### Claim 18 (depends on 14)

The compound of claim 14, wherein the moiety
is:

### Claim 19 (depends on 1)

The compound of claim 1, wherein each R3 and R4 is independently hydrogen, halo, or cyano.

### Claim 20 (depends on 1)

The compound of claim 1, wherein R3 and R4 are each independently hydrogen or C1-3 alkyl.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, wherein m is 0.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula IG:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.

### Claim 24 (depends on 1)

The compound of claim 1, wherein:
the moiety
is
n is 0 or 1;
m is 0 or 1;
L is —NH—, —O—, or —NHCH2—;
R1 is C1-3 alkyl; and
R3 and R4 are each independently hydrogen or C1-3 alkyl.

### Claim 25 (depends on 1)

The compound of claim 1, wherein:
the moiety
is
n is 0 or 1;
m is 0 or 1;
L is —NH—, —O—, or —NHCH2—;
R1 is C1-3 alkyl;
R1a is C1-3 alkyl; and
R3 and R4 are each independently hydrogen or C1-3 alkyl.

### Claim 26 (depends on 1)

The compound of claim 1, wherein the moiety

### Claim 27 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein the compound is selected from:

### Claim 28 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, and a pharmaceutically acceptable excipient.

### Claim 29

A method for treating a disease or disorder modulated, at least in part, by MutSβ, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, or 5;
p is 0, 1, 2, 3, 4, or 5;
q is 0, 1, 2, 3, or 4; provided that p+q is 2, 3, 4, or 5;
L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
X1 is O, N, or CH; provided that when X1 is O, then R1 is absent;
R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR1C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; and
each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.

### Claim 30

A method for inhibiting the activity of MutSβ, the method comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, or 5;
p is 0, 1, 2, 3, 4, or 5;
q is 0, 1, 2, 3, or 4; provided that p+q is 2, 3, 4, or 5;
L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
X1 is O, N, or CH; provided that when X1 is O, then R1 is absent;
R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; and
each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.

### Claim 31

A method for treating a neurodegenerative or neurological disease or disorder, the method comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, or 5;
p is 0, 1, 2, 3, 4, or 5;
q is 0, 1, 2, 3, or 4; provided that p+q is 2, 3, 4, or 5;
L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
X1 is O, N, or CH; provided that when X1 is O, then R1 is absent;
R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heteroaryl, or heterocyclyl; and
each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.

### Claim 32 (depends on 29)

The method of claim 29, wherein the compound, or pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is selected from Table 1.

### Claim 33 (depends on 31)

The method of claim 31, wherein the neurodegenerative or neurological disease or disorder is Huntington's disease (HD), spinal and bulbar muscular atrophy, spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 8, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, Huntington's disease-like 2, fragile X syndrome, fragile X-associated tremor/ataxia syndrome, fragile XE mental retardation, Friedreich's ataxia, myotonic dystrophy type 1, oculopharyngeal muscular dystrophy, or dentatorubro-pallidoluysian atrophy.

### Claim 34 (depends on 31)

The method of claim 31, wherein the neurodegenerative or neurological disease or disorder is Huntington's Disease (HD).

### Claim at position 34

-36. (canceled)
